Unison Advisors LLC Purchases 1,298 Shares of Pfizer Inc. (NYSE:PFE)

Unison Advisors LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 87,712 shares of the biopharmaceutical company’s stock after purchasing an additional 1,298 shares during the quarter. Unison Advisors LLC’s holdings in Pfizer were worth $2,538,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the second quarter valued at about $29,000. Quarry LP acquired a new position in Pfizer in the second quarter valued at about $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer in the fourth quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its holdings in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on PFE shares. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Down 2.1 %

PFE stock traded down $0.63 during midday trading on Thursday, hitting $29.56. The company’s stock had a trading volume of 8,567,725 shares, compared to its average volume of 37,302,039. The company’s fifty day moving average price is $29.09 and its 200 day moving average price is $28.36. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $33.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $167.50 billion, a P/E ratio of -503.25, a PEG ratio of 1.23 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.68%. Pfizer’s payout ratio is -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.